Interleukin-35 administration counteracts established murine type 1 diabetes - possible involvement of regulatory T cells

Scientific Reports

Volumn 5, Issue , 2015, Pages

  Singh, Kailash ^a   Kadesjö, Erik ^a   Lindroos, Julia ^a   Hjort, Marcus ^a   Lundberg, Marcus ^a   Espes, Daniel ^a,b   Carlsson, Per Ola ^a,b   Sandler, Stellan ^a   Thorvaldson, Lina ^a  

^a UPPSALA UNIVERSITY   (Sweden)

^b UPPSALA UNIVERSITY   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; CYTOKINE RECEPTOR; EBI3 PROTEIN, MOUSE; FORKHEAD TRANSCRIPTION FACTOR; FOXP3 PROTEIN, MOUSE; INTERLEUKIN 10; INTERLEUKIN 2; INTERLEUKIN DERIVATIVE; INTERLEUKIN-35, HUMAN; INTERLEUKIN-35, MOUSE; MINOR HISTOCOMPATIBILITY ANTIGEN; RECOMBINANT PROTEIN; STREPTOZOCIN; TRANSFORMING GROWTH FACTOR BETA;

ANIMAL; BIOSYNTHESIS; BLOOD; CHEMICALLY INDUCED; CYTOLOGY; DIABETES MELLITUS, EXPERIMENTAL; DISEASE MODEL; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; GENETICS; HELPER CELL; HUMAN; HYPERGLYCEMIA; IMMUNOLOGY; INSULIN DEPENDENT DIABETES MELLITUS; ISOLATION AND PURIFICATION; MALE; METABOLISM; MONONUCLEAR CELL; MOUSE; NONOBESE DIABETIC MOUSE; PATHOLOGY; PHENOTYPE; REGULATORY T LYMPHOCYTE; SPLEEN; THYMUS;

ANIMALS; CYTOKINES; DIABETES MELLITUS, EXPERIMENTAL; DIABETES MELLITUS, TYPE 1; DISEASE MODELS, ANIMAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; FORKHEAD TRANSCRIPTION FACTORS; HUMANS; HYPERGLYCEMIA; INTERLEUKIN-10; INTERLEUKIN-2; INTERLEUKINS; LEUKOCYTES, MONONUCLEAR; MALE; MICE; MICE, INBRED NOD; MINOR HISTOCOMPATIBILITY ANTIGENS; PHENOTYPE; RECEPTORS, CYTOKINE; RECOMBINANT PROTEINS; SPLEEN; STREPTOZOCIN; T-LYMPHOCYTES, HELPER-INDUCER; T-LYMPHOCYTES, REGULATORY; THYMUS GLAND; TRANSFORMING GROWTH FACTOR BETA;

EID: 84938493774     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep12633     Document Type: Article

References (58)

1. Atkinson, M. A., Eisenbarth, G. S. & Michels, A. W. Type 1 diabetes. Lancet 383, 69-82 (2014).
2. Diana, J. et al. Crosstalk between neutrophils, B-1a cells and plasmacytoid dendritic cells initiates autoimmune diabetes. Nat Med 19, 65-73 (2013).
3. Coppieters, K. T. et al. Demonstration of islet-autoreactive CD8 T cells in insulitic lesions from recent onset and long-term type 1. diabetes patients. J Exp Med 209, 51-60 (2012).
4. Ehrenstein, M. R. et al. Compromised function of regulatory T cells in rheumatoid arthritis and reversal by anti-TNFalpha therapy. J Exp Med 200, 277-285 (2004).
5. Bluestone, J. A. & Tang, Q. How do CD4+ CD25+ regulatory T cells control autoimmunity? Curr Opi Immunol 17, 638-642 (2005).
6. Lindley, S. et al. Defective suppressor function in CD4(+)CD25(+) T-cells from patients with type 1 diabetes. Diabetes 54, 92-99 (2005).
7. Viglietta, V., Baecher-Allan, C., Weiner, H. L. & Hafler, D. A. Loss of functional suppression by CD4+ CD25+ regulatory T cells in patients with multiple sclerosis. J Exp Med 199, 971-979 (2004).
8. Sakaguchi, S., Sakaguchi, N., Asano, M., Itoh, M. & Toda, M. Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. J Immunol 155, 1151-1164 (1995).
9. Bennett, C. L. et al. The immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome (IPEX) is caused by mutations of FOXP3. Nat Genet 27, 20-21 (2001).
10. Wildin, R. S. et al. X-linked neonatal diabetes mellitus, enteropathy and endocrinopathy syndrome is the human equivalent of mouse scurfy. Nat Genet 27, 18-20 (2001).
11. Hori, S., Nomura, T. & Sakaguchi, S. Control of regulatory T cell development by the transcription factor Foxp3. Science 299, 1057-1061 (2003).
12. Fontenot, J. D., Gavin, M. A. & Rudensky, A. Y. Foxp3 programs the development and function of CD4+ CD25+ regulatory T cells. Nat Immunol 4, 330-336 (2003).
13. Khattri, R., Cox, T., Yasayko, S. A. & Ramsdell, F. An essential role for Scurfin in CD4+ CD25+ T regulatory cells. Nat Immunol 4, 337-342 (2003).
14. Josefowicz, S. Z., Lu, L. F. & Rudensky, A. Y. Regulatory T cells: mechanisms of differentiation and function. Ann Rev Immunol 30, 531-564 (2012).
15. Vignali, D. A., Collison, L. W. & Workman, C. J. How regulatory T cells work. Nat Rev Immunol 8, 523-532 (2008).
16. Zhou, X. et al. Instability of the transcription factor Foxp3 leads to the generation of pathogenic memory T cells in vivo. Nat Immunol 10, 1000-1007 (2009).
17. Sharma, M. D. et al. Indoleamine 2,3-dioxygenase controls conversion of Foxp3+ Tregs to TH17-like cells in tumor-draining lymph nodes. Blood 113, 6102-6111 (2009).
18. Duarte, J. H., Zelenay, S., Bergman, M. L., Martins, A. C. & Demengeot, J. Natural Treg cells spontaneously differentiate into pathogenic helper cells in lymphopenic conditions. Euro J Immunol 39, 948-955 (2009).
19. Williams, L. M. & Rudensky, A. Y. Maintenance of the Foxp3-dependent developmental program in mature regulatory T cells requires continued expression of Foxp3. Nat Immunol 8, 277-284 (2007).
20. Tang, Q. et al. Central role of defective interleukin-2 production in the triggering of islet autoimmune destruction. Immunity 28, 687-697 (2008).
21. Oldenhove, G. et al. Decrease of Foxp3+ Treg cell number and acquisition of effector cell phenotype during lethal infection. Immunity 31, 772-786 (2009).
22. Vokaer, B. et al. Critical role of regulatory T cells in Th17-mediated minor antigen-disparate rejection. J Immunol 185, 3417-3425 (2010).
23. Komatsu, N. et al. Pathogenic conversion of Foxp3(+) T cells into TH17 cells in autoimmune arthritis. Nat Med 20, 62-68 (2014).
24. Wang, T. et al. Regulatory T cells in rheumatoid arthritis showed increased plasticity toward Th17 but retained suppressive function in peripheral blood. Ann Rheu Diseases 10, 2013-204228 (2014).
25. Marwaha, A. K. et al. Cutting edge: Increased IL-17-secreting T cells in children with new-onset type 1 diabetes. J Immunol 185, 3814-3818 (2010).
26. Pan, F. et al. Eos mediates Foxp3-dependent gene silencing in CD4+ regulatory T cells. Science 325, 1142-1146 (2009).
27. Like, A. A. & Rossini, A. A. Streptozotocin-induced pancreatic insulitis: new model of diabetes mellitus. Science 193, 415-417 (1976).
28. Kiniwa, Y. et al. CD8+ Foxp3+ regulatory T cells mediate immunosuppression in prostate cancer. Cli Canc Res 13, 6947-6958 (2007).
29. Thornton, A. M. et al. Expression of Helios, an Ikaros transcription factor family member, differentiates thymic-derived from peripherally induced Foxp3+ T regulatory cells. J Immunol 184, 3433-3441 (2010).
30. Weiss, J. M. et al. Neuropilin 1 is expressed on thymus-derived natural regulatory T cells, but not mucosa-generated induced Foxp3+ T reg cells. J Exp Med 209, 1723-1742, S1721 (2012).
31. Yadav, M. et al. Neuropilin-1 distinguishes natural and inducible regulatory T cells among regulatory T cell subsets in vivo. J Exp Med 209, 1713-1722, S1711-1719 (2012).
32. Singh, K., Hjort, M., Thorvaldson, L. & Sandler, S. Concomitant analysis of Helios and Neuropilin-1 as a marker to detect thymic derived regulatory T cells in naive mice. Sci Rep 5, 7767 (2015).
33. Collison, L. W. et al. The inhibitory cytokine IL-35 contributes to regulatory T-cell function. Nature 450, 566-569 (2007).
34. Collison, L. W. et al. IL-35-mediated induction of a potent regulatory T cell population. Nat Immunol 11, 1093-1101 (2010).
35. Bailey-Bucktrout, S. L. et al. Self-antigen-driven activation induces instability of regulatory T cells during an inflammatory autoimmune response. Immunity 39, 949-962 (2013).
36. Rubtsov, Y. P. et al. Stability of the regulatory T cell lineage in vivo. Science 329, 1667-1671 (2010).
37. Sharma, M. D. et al. An inherently bifunctional subset of Foxp3+ T helper cells is controlled by the transcription factor eos. Immunity 38, 998-1012 (2013).
38. Berger, A. Th1 and Th2 responses: what are they? BMJ 321, 424 (2000).
39. Niedbala, W. et al. IL-35 is a novel cytokine with therapeutic effects against collagen-induced arthritis through the expansion of regulatory T cells and suppression of Th17 cells. Eur J Immunol 37, 3021-3029 (2007).
40. Kochetkova, I., Golden, S., Holderness, K., Callis, G. & Pascual, D. W. IL-35 stimulation of CD39+ regulatory T cells confers protection against collagen II-induced arthritis via the production of IL-10. J Immunol 184, 7144-7153 (2010).
41. Bettini, M., Castellaw, A. H., Lennon, G. P., Burton, A. R. & Vignali, D. A. Prevention of autoimmune diabetes by ectopic pancreatic beta-cell expression of interleukin-35. Diabetes 61, 1519-1526 (2012).
42. Leiter, E. H. The NOD mouse: a model for insulin-dependent diabetes mellitus. Curr Prot Immunol Chapter 15, Unit 15 19 (2001).
43. Shen, P. et al. IL-35-producing B cells are critical regulators of immunity during autoimmune and infectious diseases. Nature 507, 366-370 (2014).
44. Wang, R. X. et al. Interleukin-35 induces regulatory B cells that suppress autoimmune disease. Nat Med 20, 633-641 (2014).
45. Ozer, G. et al. Serum IL-1, IL-2, TNFalpha and INFgamma levels of patients with type 1 diabetes mellitus and their siblings. JPEM 16, 203-210 (2003).
46. Lempainen, J., Harkonen, T., Laine, A., Knip, M. & Ilonen, J., Finnish, Associations of polymorphisms in non-HLA loci with autoantibodies at the diagnosis of type 1 diabetes: INS and IKZF4 associate with insulin autoantibodies. Ped Diab 14, 490-496 (2013).
47. Hasan, N. M. et al. Genetic association of the neuropilin-1 gene with type 1 diabetes in children: Neuropilin-1 expression in pancreatic islets. Diab Res Cli Prac 87, e29-32 (2010).
48. Ishida, S. et al. Coexpression of VEGF receptors VEGF-R2 and neuropilin-1 in proliferative diabetic retinopathy. Inv Ophth Vis Sci 41, 1649-1656 (2000).
49. Bondeva, T. & Wolf, G. Advanced glycation end products suppress neuropilin-1 expression in podocytes by a reduction in Sp1-dependent transcriptional activity. Ameri J Neph 30, 336-345 (2009).
50. Cai, Z. et al. Remission of systemic lupus erythematosus disease activity with regulatory cytokine IL-35 in MRL/lpr mice. Clin Exp Immunol, doi: 10.1002/cei.12639 (2015).
51. Nakano, S. et al. Immunoregulatory role of IL-35 in T cells of patients with rheumatoid arthritis. Rheumatology, doi: 10.1093/rheumatology/keu528 (2015).
52. Zhou, Y., Zhang, H. & Li, Y. IL-35 expression in peripheral blood CD4(+) T cells from chronic hepatitis B virus-infected patients directly correlates with virus load. Cytokine 73, 169-175 (2015).
53. Ding, L. F. et al. Effects of sublingual immunotherapy on serum IL-17 and IL-35 levels in children with allergic rhinitis or asthma. Zhongguo Dang Dai Er Ke Za Zhi 16, 1206-1210 (2014).
54. Liu, Y. et al. IL-35 mitigates murine acute graft-versus-host disease with retention of graft-versus-leukemia effects. Leukemia 29, 939-946 (2015).
55. Chen, C. et al. Decreased concentration of IL-35 in plasma of patients with asthma and COPD. Asian Pac J Aller Immunol 32, 211-217 (2014).
56. Yang, Y. et al. Decreased IL-35 levels in patients with immune thrombocytopenia. Hum Immunol 75, 909-913 (2014).
57. Rossini, A. A., Williams, R. M., Appel, M. C. & Like, A. A. Sex differences in the multiple-dose streptozotocin model of diabetes. Endocrinology 103, 1518-1520 (1978).
58. Rydgren, T., Oster, E., Sandberg, M. & Sandler, S. Administration of IL-1 trap prolongs survival of transplanted pancreatic islets to type 1 diabetic NOD mice. Cytokine 63, 123-129 (2013).